- Press releases
- Country: United States
Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman
SAN FRANCISCO, Nov. 19, 2026 /PRNewswire/ -- On November 13, 2026, investors in Candel Therapeutics (NASDAQ: CADL) saw the price of their shares tumble 26% on the company's announcement that it is delaying the submission of its biologics license application ("BLA") for its most advanced...